Early low‐dose erythropoiesis‐stimulating agent therapy and progression of moderate chronic kidney disease: a randomized, placebo‐controlled trial

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Nephrology, Dialysis and Transplantation

• Publication date

  2017-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/ndt/gfw418PMID 28186540
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Estimated GFR Trajectories of People Entering CKD Stage 4 and Subsequent Kidney Disease Outcomes and Mortality.

  2016cited by this paper
• Pleiotropic and Renoprotective Effects of Erythropoietin Beta on Experimental Diabetic Nephropathy Model

  2016cited by this paper
• Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysis.

  2016cited by this paper
• Multinational Assessment of Accuracy of Equations for Predicting Risk of Kidney Failure: A Meta-analysis.

  2016cited by this paper
• Dietary risk factors for incidence or progression of chronic kidney disease in individuals with type 2 diabetes in the European Union.

  2015cited by this paper
• Modifiable lifestyle and social factors affect chronic kidney disease in high-risk individuals with type 2 diabetes mellitus.

  2015cited by this paper
• Differences in risk factors for the onset of albuminuria and decrease in glomerular filtration rate in people with Type 2 diabetes mellitus: implications for the pathogenesis of diabetic kidney disease

  2015cited by this paper
• Looking to the future: predicting renal replacement outcomes in a large community cohort with chronic kidney disease.

  2015cited by this paper
• Impacts of Recombinant Human Erythropoietin Treatment During Predialysis Periods on the Progression of Chronic Kidney Disease in a Large‐Scale Cohort Study (Co‐JET study)

  2014cited by this paper
• Kidney Disease and Related Findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study

  2014cited by this paper
• Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease

  2014cited by this paper
• Diabetic Retinopathy and Microalbuminuria Can Predict Macroalbuminuria and Renal Function Decline in Japanese Type 2 Diabetic Patients

  2013cited by this paper
• Derivation and Validation of a Renal Risk Score for People With Type 2 Diabetes

  2013cited by this paper
• Erythropoietin ameliorates podocyte injury in advanced diabetic nephropathy in the db/db mouse.

  2013cited by this paper
• Validation of the kidney failure risk equation in European CKD patients.

  2013cited by this paper
• Kidney Disease and Related Findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study

  2013cited by this paper
• The influence of the pleiotropic action of erythropoietin and its derivatives on nephroprotection

  2013cited by this paper
• Factors that may influence estimated glomerular filtration rate in patients with excellent graft function 10 years posttransplant.

  2013cited by this paper
• Conversion from Epoetin and Darbepoetin to C.E.R.A. in Non-Dialysis CKD Patients: A Multicenter Italian Prospective Study in Nephrology Practice

  2013cited by this paper
• Diabetic Retinopathy and Microalbuminuria Can Predict Macroalbuminuria and Renal Function Decline in Japanese Type 2 Diabetic Patients Japan Diabetes Complications Study

  2013cited by this paper
• Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial.

  2012cited by this paper
• A multicenter, randomized trial of increased mycophenolic acid dose using enteric-coated mycophenolate sodium with reduced tacrolimus exposure in maintenance kidney transplant recipients.

  2012cited by this paper
• The Primavera study protocol design: evaluating the effect of continuous erythropoiesis receptor activator (C.E.R.A.) on renal function in non-anemic patients with chronic kidney disease.

  2011influential reference
• Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study.

  2011cited by this paper
• A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease

  2010influential reference
• Perspectives in renal disease progression: the endothelium as a treatment target in chronic kidney disease.

  2010cited by this paper
• Health-related quality of life and hemoglobin levels in chronic kidney disease patients.

  2009cited by this paper
• A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

  2009cited by this paper
• Achieving Chronic Kidney Disease Treatment Targets in Renal Transplant Recipients: Results From a Cross-Sectional Study in Spain

  2009cited by this paper
• A new equation to estimate glomerular filtration rate.

  2009cited by this paper
• Anemia and cardiovascular risk in the patient with kidney disease.

  2008cited by this paper
• The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes.

  2008cited by this paper
• Influence of Time of Rejection on Long-Term Graft Survival in Renal Transplantation

  2008cited by this paper
• Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study.

  2007cited by this paper
• Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease

  2007influential reference
• Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) study.

  2007cited by this paper
• Role of anemia in progression of chronic kidney disease.

  2006cited by this paper
• Estimated One-Year Glomerular Filtration Rate is the Best Predictor of Long-term Graft Function Following Renal Transplant

  2006cited by this paper
• Reduced glomerular filtration rate in pre-dialysis non-diabetic chronic kidney disease patients is associated with impaired baroreceptor sensitivity and reduced vascular compliance.

  2006cited by this paper
• Association of anemia with outcomes in men with moderate and severe chronic kidney disease.

  2006cited by this paper
• Correction of anemia with epoetin alfa in chronic kidney disease.

  2006cited by this paper
• Normalization of hemoglobin level in patients with chronic kidney disease and anemia.

  2006cited by this paper
• Effect of early correction of anemia on the progression of CKD.

  2006cited by this paper
• The growing volume of diabetes-related dialysis: a population based study.

  2004cited by this paper
• Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial.

  2004cited by this paper
• Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

  2001cited by this paper
• EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES AND NEPHROPATHY EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY

  2001cited by this paper
• Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate.

  2000cited by this paper
• The role of underlying nephropathy in the progression of renal disease.

  2000cited by this paper
• A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation

  1999cited by this paper
• Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients.

  1997cited by this paper
• Plasma aldosterone regulation in anephric man.

  1973cited by this paper
• Downloaded from http://hyper.ahajournals.org / by guest on February 23, 2013Essential Role of Endothelial Nitric Oxide Synthase in Vascular Effects of Erythropoietin

  year unknowncited by this paper

• Evaluation of the nephroprotective strategy effectiveness in the late stages of chronic kidney disease

  2023cites this paper
• Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.

  2023cites this paper
• Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors

  2022cites this paper
• Current and Emerging Drugs in the Treatment of Anemia in Patients with Chronic Kidney Disease.

  2020cites this paper
• CKD Progression

  2019cites this paper
• The interaction between post-transplant anemia and allograft function in kidney transplantation: The Japan Academic Consortium of Kidney Transplantation-II study

  2019cites this paper
• Erythropoiesis stimulating agents and nephroprotection: is there any room for new trials?

  2017cites this paper
• Is trough level variability the new tool for identifying patients at risk for rejection after transplantation ?

  2017influential citation
• Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease.

  2017cites this paper